The White Home has not responded to a number of requests for remark. Makes an attempt to attain Califf had been unsuccessful.
Califf, a heart specialist by coaching, beforehand served as FDA commissioner for almost a yr on the tail finish of the Obama administration. He additionally spent two years as deputy commissioner of the FDA’s medical merchandise and tobacco workplace and labored carefully with Biden on the then-vice president’s Most cancers Moonshot Initiative.
He emerged in current weeks as the White Home’s prime candidate to run the FDA, pushed largely by his preexisting data of the company’s internal workings and bipartisan enchantment.
Califf garnered broad assist throughout his first stint as FDA commissioner, successful affirmation by an 89-4 margin. This time round, he is probably to be buoyed by endorsements from a bipartisan group of fellow former FDA commissioners — as nicely as public well being consultants who’ve urged Biden for months to decide on a nominee.
Cytokinetics CEO Robert Blum informed POLITICO that Califf character and monitor file is nicely suited to the second, describing him as somebody who “instructions plenty of respect” regardless of an typically low-key demeanor. Califf joined Cytokinetics’ board of administrators in February 2018, a place he’ll probably step down from.
“He’s any person who’s deeply excited by scientific proof and principally constructed his profession round it,” Blum stated. “Rob understands the suitable correct interaction between the non-public sector and the general public sector, each by way of science, business and regulatory issues. He is definitely not a shill for anyone stakeholder. He demonstrated that when he was already at FDA.”
Regardless of the company’s outstanding function within the Covid-19 response, it has been with no everlasting chief since Biden took workplace. The White Home had initially thought of nominating longtime regulator and appearing Commissioner Janet Woodcock to the function. However her candidacy stalled within the face of Democratic opposition over her monitor file on opioids and a more moderen resolution to green-light a controversial Alzheimer’s drug.
“It is a very unorthodox factor that he could be himself requested to return, however he is a fairly unusual individual,” Blum stated. “I do not know if that is the case for lots of different folks the place they’d select to return like that. I feel he is acquired an actual name to obligation proper now, given the politicization of what is taking place round Covid and different issues.”
A number of different candidates — together with Biotechnology Innovation Group CEO Michelle McMurry-Heath and Dana-Farber Most cancers Institute President Laurie Glimcher — had been additionally thought of and finally dominated out through the wide-ranging, nine-month search course of.
Nonetheless, Califf may face questions of his personal. As well as to working on the Duke Medical Analysis Institute, he has helped lead well being coverage at Google guardian firm Alphabet since 2019 — a job that will draw scrutiny from the Senate’s left flank.
Sens. Joe Manchin (D-W.Va.) and Sen. Bernie Sanders (I-Vt.) additionally voiced issues about Califf throughout his affirmation course of in 2016, with each questioning his ties to the drug business. Califf on the time had written papers with pharmaceutical business executives and consulted for drug and machine makers.
But within the run-up to Califf’s official nomination, a number of outdoors well being consultants hailed his choice as one that might deliver long-sought stability to an company that is spent the final two years below intense strain.
“From the attitude of fulfilling FDA’s tobacco mission, Dr. Califf could be an outstanding alternative,” Marketing campaign for Tobacco-Free Youngsters President Matthew Myers informed POLITICO, saying the previous commissioner has a file of encouraging the company to take “robust motion to scale back tobacco use.”